PEA shown to inhibit COVID-19 by dual mechanisms, trial results to be out in Q3 – Gencor 29-Jun-2022 By Tingmin Koe Palmitoylethanolamide (PEA) has shown to inhibit the COVID-19 virus in both in-silico and in-vitro settings, and positive findings from a clinical trial are expected to be published in Q3, says functional ingredient firm Gencor.